Anacor Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results

Published: May 11, 2012

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the first quarter ended March 31, 2012. “Our Phase 3 trials of tavaborole in onychomycosis are progressing well, with retention and compliance rates performing better than our assumptions. We are looking forward to reporting data from our first Phase 3 trial in January 2013,” said David Perry, CEO of Anacor Pharmaceuticals. “We are also preparing to initiate additional Phase 2 trials of AN2728 in atopic dermatitis and expect to have data from one of these trials in the second half of this year.”

Back to news